Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 79Myelodysplastic Syndromes 42Leukemia 23Leukemia, Myelomonocytic, Chronic 20Congenital Abnormalities 10Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Recurrence 7Neoplasms 7Myeloproliferative Disorders 7Blast Crisis 7Leukemia, Myelogenous, Chronic, BCR-ABL Positive 6Leukemia, Myeloid, Accelerated Phase 5Carcinoma, Non-Small-Cell Lung 5Thrombocythemia, Essential 4Primary Myelofibrosis 4Polycythemia Vera 4Leukemia, Lymphocytic, Chronic, B-Cell 4Myelodysplastic-Myeloproliferative Diseases 3Lymphoma, Mantle-Cell 3Lymphoma, Large B-Cell, Diffuse 3Lung Neoplasms 3Leukemia, Myelomonocytic, Acute 3Leukemia, Monocytic, Acute 3Burkitt Lymphoma 3Anemia, Refractory, with Excess of Blasts 3Anemia, Refractory 3Small Cell Lung Carcinoma 2Neuroblastoma 2Neoplasm Metastasis 2Mesothelioma, Malignant 2

Interventions

midostaurin 1Nivolumab 1Injections 1Decitabine 1Cytarabine 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × GATA2 Deficiency × Decitabine × Clear all
NCT03092674 2025-01-16

Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

National Cancer Institute (NCI)

Phase 2/3 Completed
76 enrolled 16 charts
MyeloidOther hematologic neoplasm

GATA2 Deficiency, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡